AU2018274655B2 - Viral expression construct comprising a fibroblast growth factor 21 (FGF21) coding sequence - Google Patents
Viral expression construct comprising a fibroblast growth factor 21 (FGF21) coding sequence Download PDFInfo
- Publication number
- AU2018274655B2 AU2018274655B2 AU2018274655A AU2018274655A AU2018274655B2 AU 2018274655 B2 AU2018274655 B2 AU 2018274655B2 AU 2018274655 A AU2018274655 A AU 2018274655A AU 2018274655 A AU2018274655 A AU 2018274655A AU 2018274655 B2 AU2018274655 B2 AU 2018274655B2
- Authority
- AU
- Australia
- Prior art keywords
- fgf21
- hfd
- mofgf21
- nucleotide sequence
- promoter
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/25—Animals on a special diet
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0362—Animal model for lipid/glucose metabolism, e.g. obesity, type-2 diabetes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
- C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
- C12N2310/141—MicroRNAs, miRNAs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Environmental Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Gastroenterology & Hepatology (AREA)
- Animal Husbandry (AREA)
- Mycology (AREA)
- Biodiversity & Conservation Biology (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2025203001A AU2025203001A1 (en) | 2017-05-24 | 2025-04-29 | Viral expression construct comprising a fibroblast growth factor 21 (FGF21) coding sequence |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES201700615 | 2017-05-24 | ||
| EP17172818 | 2017-05-24 | ||
| EP17172818.1 | 2017-05-24 | ||
| ES201700615 | 2017-05-24 | ||
| PCT/EP2018/063707 WO2018215613A1 (en) | 2017-05-24 | 2018-05-24 | Viral expression construct comprising a fibroblast growth factor 21 (fgf21) coding sequence |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2025203001A Division AU2025203001A1 (en) | 2017-05-24 | 2025-04-29 | Viral expression construct comprising a fibroblast growth factor 21 (FGF21) coding sequence |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2018274655A1 AU2018274655A1 (en) | 2019-12-19 |
| AU2018274655B2 true AU2018274655B2 (en) | 2025-01-30 |
Family
ID=62620819
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2018274655A Active AU2018274655B2 (en) | 2017-05-24 | 2018-05-24 | Viral expression construct comprising a fibroblast growth factor 21 (FGF21) coding sequence |
| AU2025203001A Pending AU2025203001A1 (en) | 2017-05-24 | 2025-04-29 | Viral expression construct comprising a fibroblast growth factor 21 (FGF21) coding sequence |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2025203001A Pending AU2025203001A1 (en) | 2017-05-24 | 2025-04-29 | Viral expression construct comprising a fibroblast growth factor 21 (FGF21) coding sequence |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20200102361A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3630160A1 (cg-RX-API-DMAC7.html) |
| JP (3) | JP7778469B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN110913886A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2018274655B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112019024608A2 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2019013982A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2018215613A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102765034B1 (ko) | 2017-05-24 | 2025-02-11 | 유니버시타트 아우토노마 데 바르셀로나 | 섬유아세포 성장 인자 21 (fgf21) 코딩 서열을 포함하는 바이러스 발현 컨스트럭트 |
| BR112019024608A2 (pt) * | 2017-05-24 | 2020-06-23 | Universitat Autonoma De Barcelona | Construto de expressão viral que compreende uma sequência de codificação do fator de crescimento de fibroblastos 21 (fgf21) |
| GB201818816D0 (en) * | 2018-11-19 | 2019-01-02 | Synpromics Ltd | Regulatory nucleic acid sequences |
| IL283452B2 (en) * | 2018-11-26 | 2026-04-01 | Univ Barcelona Autonoma | FIBROBLAST GROWTH FACTOR 21 (FGF21)-BASED GENE THERAPY |
| ES2948620T3 (es) | 2019-07-10 | 2023-09-14 | Masonic Medical Res Laboratory | Vgll4 con elemento regulador CIS de UCP-1 y método de uso del mismo |
| MX2022004353A (es) | 2019-10-17 | 2022-07-19 | Casete de transferencia de aav. | |
| CN115916985A (zh) * | 2020-05-26 | 2023-04-04 | 巴塞罗那自治大学 | 用于中枢神经系统障碍的成纤维细胞生长因子21(fgf21)基因疗法 |
| CN113956344A (zh) * | 2021-10-14 | 2022-01-21 | 江南大学 | 一种新型治疗肝癌的fgf类似物及其应用 |
| CN114010666B (zh) * | 2021-10-22 | 2024-05-07 | 上海交通大学 | 溶瘤病毒、parp抑制剂及pd-1抗体在制备抗肿瘤药物中的应用 |
| CN114316018A (zh) * | 2021-11-26 | 2022-04-12 | 江南大学 | 一种fgf21蛋白类似物及其应用 |
| CN118460618A (zh) * | 2022-04-19 | 2024-08-09 | 康霖生物科技(杭州)有限公司 | 一种用于遗传性凝血因子缺乏病治疗的核酸构建体 |
| EP4598590A4 (en) * | 2022-10-08 | 2026-05-27 | Lingyi Biotech Co Ltd | CONSTRUCTION TO IMPROVE GENE EXPRESSION |
| WO2025158406A1 (en) * | 2024-01-26 | 2025-07-31 | Source Bio, Inc. | Compositions for adipose tissue targeting and uses thereof |
| CN118389554A (zh) * | 2024-05-10 | 2024-07-26 | 三峡大学 | 一种提高fgf-21持续表达水平和稳定性的aav重组病毒及其应用 |
| WO2025240610A2 (en) * | 2024-05-14 | 2025-11-20 | Rejuvenate Bio Inc | Fgf21 gene therapy and methods therefor |
| WO2026028137A1 (en) * | 2024-07-31 | 2026-02-05 | Universitat Autònoma De Barcelona | Fibroblast growth factor 21 (fgf21) gene therapy |
| WO2026133103A1 (en) * | 2024-12-16 | 2026-06-25 | Universitat Autònoma De Barcelona | Aav vectors for delivery of nucleic acids encoding fgf21 and methods of treating lung diseases using the same |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013006486A2 (en) * | 2011-07-01 | 2013-01-10 | Ngm Biopharmaceuticals, Inc. | Compositions, uses and methods for treatment of metabolic disorders and diseases |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
| US5436146A (en) | 1989-09-07 | 1995-07-25 | The Trustees Of Princeton University | Helper-free stocks of recombinant adeno-associated virus vectors |
| US6268213B1 (en) | 1992-06-03 | 2001-07-31 | Richard Jude Samulski | Adeno-associated virus vector and cis-acting regulatory and promoter elements capable of expressing at least one gene and method of using same for gene therapy |
| US5869305A (en) | 1992-12-04 | 1999-02-09 | The University Of Pittsburgh | Recombinant viral vector system |
| US5464758A (en) | 1993-06-14 | 1995-11-07 | Gossen; Manfred | Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters |
| US6204059B1 (en) | 1994-06-30 | 2001-03-20 | University Of Pittsburgh | AAV capsid vehicles for molecular transfer |
| US5741683A (en) | 1995-06-07 | 1998-04-21 | The Research Foundation Of State University Of New York | In vitro packaging of adeno-associated virus DNA |
| US6093570A (en) | 1995-06-07 | 2000-07-25 | The University Of North Carolina At Chapel Hill | Helper virus-free AAV production |
| US5952221A (en) | 1996-03-06 | 1999-09-14 | Avigen, Inc. | Adeno-associated virus vectors comprising a first and second nucleic acid sequence |
| US6133027A (en) | 1996-08-07 | 2000-10-17 | City Of Hope | Inducible expression system |
| EP1007637B1 (en) | 1997-04-14 | 2004-06-30 | Cell Genesys, Inc. | Methods for increasing the efficiency of recombinant aav product |
| US6207455B1 (en) | 1997-05-01 | 2001-03-27 | Lung-Ji Chang | Lentiviral vectors |
| CN1247788C (zh) | 1997-05-13 | 2006-03-29 | 北卡罗来纳-查佩尔山大学 | 基于慢病毒的基因转移载体 |
| US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
| US6218181B1 (en) | 1998-03-18 | 2001-04-17 | The Salk Institute For Biological Studies | Retroviral packaging cell line |
| US6146874A (en) | 1998-05-27 | 2000-11-14 | University Of Florida | Method of preparing recombinant adeno-associated virus compositions |
| EP1135468B1 (en) | 1998-11-10 | 2010-01-06 | University Of North Carolina At Chapel Hill | Virus vectors and methods of making and administering the same |
| DE19909769A1 (de) | 1999-03-05 | 2000-09-07 | Bundesrepublik Deutschland Let | Von SIVagm abgeleitete lentivirale Vektoren, Verfahren zu ihrer Herstellung und ihre Verwendung zur Genübertragung in Säugerzellen |
| AU6814901A (en) | 2000-06-01 | 2001-12-11 | Univ North Carolina | Methods and compounds for controlled release of recombinant parvovirus vectors |
| AU2001292881A1 (en) * | 2000-09-20 | 2002-04-02 | The Regents Of The University Of California | Use of recombinant gene delivery vectors for treating or preventing diseases of the eye |
| AU2003274397A1 (en) | 2002-06-05 | 2003-12-22 | University Of Florida | Production of pseudotyped recombinant aav virions |
| WO2013033452A2 (en) * | 2011-08-31 | 2013-03-07 | Amgen Inc. | Method of treating or ameliorating type 1 diabetes using fgf21 |
| EP2692868A1 (en) * | 2012-08-02 | 2014-02-05 | Universitat Autònoma De Barcelona | Adeno-associated viral (AAV) vectors useful for transducing adipose tissue |
| US9290557B2 (en) * | 2012-11-28 | 2016-03-22 | Ngm Biopharmaceuticals, Inc. | Compositions comprising variants and fusions of FGF19 polypeptides |
| EP3798228A1 (en) * | 2012-11-28 | 2021-03-31 | NGM Biopharmaceuticals, Inc. | Compositions and methods for treatment of metabolic disorders and diseases |
| CN105916990B (zh) * | 2013-08-02 | 2020-02-04 | 巴塞罗那自治大学 | 用于转导脂肪组织的腺相关病毒载体 |
| CN109844124B (zh) * | 2016-05-20 | 2023-10-03 | 哈佛学院董事及会员团体 | 年龄相关疾病和病症的基因治疗方法 |
| BR112019024608A2 (pt) | 2017-05-24 | 2020-06-23 | Universitat Autonoma De Barcelona | Construto de expressão viral que compreende uma sequência de codificação do fator de crescimento de fibroblastos 21 (fgf21) |
| IL283452B2 (en) * | 2018-11-26 | 2026-04-01 | Univ Barcelona Autonoma | FIBROBLAST GROWTH FACTOR 21 (FGF21)-BASED GENE THERAPY |
-
2018
- 2018-05-24 BR BR112019024608-8A patent/BR112019024608A2/pt unknown
- 2018-05-24 US US16/615,854 patent/US20200102361A1/en not_active Abandoned
- 2018-05-24 EP EP18731359.8A patent/EP3630160A1/en active Pending
- 2018-05-24 MX MX2019013982A patent/MX2019013982A/es unknown
- 2018-05-24 AU AU2018274655A patent/AU2018274655B2/en active Active
- 2018-05-24 WO PCT/EP2018/063707 patent/WO2018215613A1/en not_active Ceased
- 2018-05-24 CN CN201880047871.5A patent/CN110913886A/zh active Pending
- 2018-05-24 JP JP2019565341A patent/JP7778469B2/ja active Active
-
2023
- 2023-05-30 JP JP2023089121A patent/JP7888501B2/ja active Active
-
2025
- 2025-04-29 AU AU2025203001A patent/AU2025203001A1/en active Pending
-
2026
- 2026-03-31 JP JP2026059364A patent/JP2026119083A/ja active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013006486A2 (en) * | 2011-07-01 | 2013-01-10 | Ngm Biopharmaceuticals, Inc. | Compositions, uses and methods for treatment of metabolic disorders and diseases |
Non-Patent Citations (1)
| Title |
|---|
| ZHANG, J., et al., 2017, "Chronic Over-expression of Fibroblast Growth Factor 21 Increases Bile Acid Biosynthesis by Opposing FGF15/19 Action", EBIOMEDICINE, 15, pages 173-183 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2018215613A1 (en) | 2018-11-29 |
| JP7888501B2 (ja) | 2026-07-13 |
| JP2023109992A (ja) | 2023-08-08 |
| AU2025203001A1 (en) | 2025-05-22 |
| RU2019142845A3 (cg-RX-API-DMAC7.html) | 2021-09-20 |
| EP3630160A1 (en) | 2020-04-08 |
| AU2025203001A9 (en) | 2026-03-05 |
| JP2020530977A (ja) | 2020-11-05 |
| BR112019024608A2 (pt) | 2020-06-23 |
| AU2018274655A1 (en) | 2019-12-19 |
| US20200102361A1 (en) | 2020-04-02 |
| RU2019142845A (ru) | 2021-06-24 |
| JP7778469B2 (ja) | 2025-12-02 |
| MX2019013982A (es) | 2020-07-22 |
| CN110913886A (zh) | 2020-03-24 |
| JP2026119083A (ja) | 2026-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2025203001A1 (en) | Viral expression construct comprising a fibroblast growth factor 21 (FGF21) coding sequence | |
| AU2018229561B2 (en) | Recombinant adenoviruses and use thereof | |
| KR20220125332A (ko) | Pcsk9의 표적화를 위한 조성물 및 방법 | |
| DK2324120T3 (en) | Manipulating SNF1 protein kinase OF REVISION OF OIL CONTENT IN OLEAGINOUS ORGANISMS | |
| AU2017220789B2 (en) | Compositions and Methods for Modifying Genomes | |
| US7527966B2 (en) | Gene regulation in transgenic animals using a transposon-based vector | |
| DK2087105T3 (da) | Delta 17-desaturase og anvendelse heraf ved fremstilling af flerumættede fedtsyrer | |
| CN101213203A (zh) | 在转录后水平调节核酸表达的方法和组合物 | |
| AU2016370590B2 (en) | Composition for treatment of Crigler-Najjar syndrome | |
| KR20070085669A (ko) | 고농도의 아라키돈산을 생성하는 야로위아 리폴리티카 균주 | |
| KR20140099224A (ko) | 케토-아이소발레레이트 데카르복실라제 효소 및 이의 이용 방법 | |
| PT1984512T (pt) | Sistema de expressão génica utilizando excisão-união em insetos | |
| CN113166779A (zh) | 调控的基因编辑系统 | |
| KR20240029020A (ko) | Dna 변형을 위한 crispr-트랜스포손 시스템 | |
| KR20230017845A (ko) | 중추 신경계 장애에 대한 섬유아세포 성장 인자 21(fgf21) 유전자 요법 | |
| DK2935601T3 (en) | RECOMBINANT MICROBELL CELLS PRODUCING AT LEAST 28% EICOSAPENTAIC ACID AS DRY WEIGHT | |
| KR20180081817A (ko) | 감소된 clr1 활성을 갖는 사상 진균에서 단백질을 생산하는 방법 | |
| CN115247188A (zh) | 试剂盒及其在构建高表达猪II型5α-还原酶的脱发模型猪核移植供体细胞中的应用 | |
| CN115247189A (zh) | 一种表达人源II型5α-还原酶的脱发模型猪核移植供体细胞的构建方法 | |
| KR102765034B1 (ko) | 섬유아세포 성장 인자 21 (fgf21) 코딩 서열을 포함하는 바이러스 발현 컨스트럭트 | |
| RU2839576C2 (ru) | Вирусная экспрессионная конструкция, содержащая кодирующую последовательность фактора роста фибробластов 21 (fgf21) | |
| US20240415978A1 (en) | Anellovectors for delivery of effectors to the central nervous system | |
| KR20140043890A (ko) | 조절된 유전자 발현 시스템 및 그의 작제물 | |
| WO2002038613A2 (en) | Modified recombinase | |
| KR20220016100A (ko) | 인슐린 유전자 요법 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |